Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982079 | 0.95 | CTSS (0.67) | CTSSCREBBPKCNK3 | |
| SCHEMBL2973880 | 0.94 | CTSS (0.66) | CTSSCREBBPKCNK3 | |
| SCHEMBL2978757 | 0.94 | CTSS (0.66) | CTSSCREBBPKCNK3 | |
| SCHEMBL2972789 | 0.92 | CTSS (0.71) | CTSSCREBBPKCNK3 | |
| SCHEMBL2982159 | 0.91 | CTSS (0.66) | CTSSCREBBPKCNK3 | |
| SCHEMBL2983051 | 0.91 | CTSS (0.70) | CTSSCREBBPKCNK3 | |
| SCHEMBL2984618 | 0.91 | CTSS (0.65) | CTSSCREBBPKCNK3 | |
| SCHEMBL2979212 | 0.90 | CTSS (0.68) | CTSSCREBBPKCNK3 | |
| SCHEMBL2969850 | 0.88 | CTSS (0.88) | CTSS | |
| SCHEMBL2978861 | 0.87 | CTSS (0.73) | CTSSCREBBPKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | CTSS, CTSV, CTSZ | CTSS 1/4885CREBBP 2715/4885KCNK3 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.